Literature DB >> 21702015

Biosimilars: the debate continues.

Robert A Colbert1, Bruce N Cronstein.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21702015      PMCID： PMC3200229          DOI： 10.1002/art.30505

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  3 in total

Review 1.  Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.

Authors:  Wolfgang Jelkmann
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

2.  Hearing shines spotlight on biosimilar controversies.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

3.  Biosimilars encircle Rituxan, US debates innovator exclusivity.

Authors:  Karen Carey
Journal:  Nat Biotechnol       Date:  2011-03       Impact factor: 54.908
  3 in total
  8 in total

1.  Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.

Authors:  David Grabowski; Bradley Henderson; Dennis Lam; Edward C Keystone; Carter Thorne; Shahin Jamal; Janet Pope; Boulos Haraoui; Daming Lin; Leigh Revers
Journal:  Clin Rheumatol       Date:  2015-01-15       Impact factor: 2.980

Review 2.  Subsequent entry biologics/biosimilars: a viewpoint from Canada.

Authors:  Anthony S Russell; Vandana Ahluwalla; Cheryl Barnabe; Shahin Jamal; Robert C Offer; Wojciech P Olszynski; Kam Shojania; Boulos Haraoui
Journal:  Clin Rheumatol       Date:  2012-08-26       Impact factor: 2.980

3.  Biosimilars in rheumatology: a view from Latin America.

Authors:  Eduardo Mysler; Morton Scheinberg
Journal:  Clin Rheumatol       Date:  2012-08-24       Impact factor: 2.980

4.  Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

Authors:  Kaniz Afroz Tanni; Cong Bang Truong; Sura Almahasis; Jingjing Qian
Journal:  BioDrugs       Date:  2021-01-13       Impact factor: 5.807

5.  Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists.

Authors:  Sadia Shakeel; Mohamed Azmi Hassali; Hina Rehman; Anees Ur Rehman; Jaya Muneswarao
Journal:  Int J Gen Med       Date:  2020-11-11

6.  Patient attitudes and understanding about biosimilars: an international cross-sectional survey.

Authors:  Ira Jacobs; Ena Singh; K Lea Sewell; Ahmad Al-Sabbagh; Lesley G Shane
Journal:  Patient Prefer Adherence       Date:  2016-05-26       Impact factor: 2.711

Review 7.  The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.

Authors:  Eva Rahman Kabir; Shannon Sherwin Moreino; Mohammad Kawsar Sharif Siam
Journal:  Biomolecules       Date:  2019-08-24

Review 8.  Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.

Authors:  Richard Markus; Jennifer Liu; Monica Ramchandani; Diana Landa; Teresa Born; Primal Kaur
Journal:  BioDrugs       Date:  2017-06       Impact factor: 5.807
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.